CA3158781A1 - Methods of treating the symptoms of autism spectrum disorder - Google Patents
Methods of treating the symptoms of autism spectrum disorderInfo
- Publication number
- CA3158781A1 CA3158781A1 CA3158781A CA3158781A CA3158781A1 CA 3158781 A1 CA3158781 A1 CA 3158781A1 CA 3158781 A CA3158781 A CA 3158781A CA 3158781 A CA3158781 A CA 3158781A CA 3158781 A1 CA3158781 A1 CA 3158781A1
- Authority
- CA
- Canada
- Prior art keywords
- patient
- points
- treating
- treatment
- prior
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962925023P | 2019-10-23 | 2019-10-23 | |
| US62/925,023 | 2019-10-23 | ||
| US202063011715P | 2020-04-17 | 2020-04-17 | |
| US63/011,715 | 2020-04-17 | ||
| PCT/US2020/057133 WO2021081376A1 (en) | 2019-10-23 | 2020-10-23 | Methods of treating the symptoms of autism spectrum disorder |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3158781A1 true CA3158781A1 (en) | 2021-04-29 |
Family
ID=75620321
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3158781A Pending CA3158781A1 (en) | 2019-10-23 | 2020-10-23 | Methods of treating the symptoms of autism spectrum disorder |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20220387396A1 (https=) |
| EP (2) | EP4681714A3 (https=) |
| JP (2) | JP7766026B2 (https=) |
| KR (1) | KR20220122602A (https=) |
| CN (1) | CN114901270A (https=) |
| AU (1) | AU2020370479A1 (https=) |
| CA (1) | CA3158781A1 (https=) |
| DK (1) | DK4048249T3 (https=) |
| ES (1) | ES3056138T3 (https=) |
| FI (1) | FI4048249T3 (https=) |
| HR (1) | HRP20251489T1 (https=) |
| IL (1) | IL292367B1 (https=) |
| LT (1) | LT4048249T (https=) |
| MX (2) | MX2022004910A (https=) |
| PT (1) | PT4048249T (https=) |
| SI (1) | SI4048249T1 (https=) |
| WO (1) | WO2021081376A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022079307A1 (en) * | 2020-10-16 | 2022-04-21 | Purposeful Ike | Compositions and uses thereof |
| US20240189240A1 (en) * | 2021-03-25 | 2024-06-13 | Maplight Therapeutics, Inc. | Pharmaceutical compositions comprising zolmitriptan |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8236787B2 (en) * | 2008-12-09 | 2012-08-07 | Synthonics, Inc. | Frequency modulated drug delivery (FMDD) |
| BR112016027096B1 (pt) * | 2014-05-19 | 2023-04-11 | Northeastern University | Composições farmacêuticas e compostos de receptores-alvo de serotonina e seus usos |
| HUE059559T2 (hu) * | 2015-02-25 | 2022-12-28 | Univ California | 5HT agonisták az epilepsziás rendellenességek kezelésére |
| KR102534545B1 (ko) * | 2015-05-22 | 2023-05-18 | 아리조나 보드 오브 리젠츠 온 비하프 오브 아리조나 스테이트 유니버시티 | 자폐 스펙트럼 장애 및 관련된 증상을 치료하는 방법 |
-
2020
- 2020-10-23 ES ES20879266T patent/ES3056138T3/es active Active
- 2020-10-23 HR HRP20251489TT patent/HRP20251489T1/hr unknown
- 2020-10-23 CN CN202080087440.9A patent/CN114901270A/zh active Pending
- 2020-10-23 IL IL292367A patent/IL292367B1/en unknown
- 2020-10-23 US US17/770,535 patent/US20220387396A1/en active Pending
- 2020-10-23 FI FIEP20879266.3T patent/FI4048249T3/fi active
- 2020-10-23 WO PCT/US2020/057133 patent/WO2021081376A1/en not_active Ceased
- 2020-10-23 LT LTEPPCT/US2020/057133T patent/LT4048249T/lt unknown
- 2020-10-23 DK DK20879266.3T patent/DK4048249T3/da active
- 2020-10-23 MX MX2022004910A patent/MX2022004910A/es unknown
- 2020-10-23 SI SI202030689T patent/SI4048249T1/sl unknown
- 2020-10-23 KR KR1020227017060A patent/KR20220122602A/ko active Pending
- 2020-10-23 AU AU2020370479A patent/AU2020370479A1/en active Pending
- 2020-10-23 EP EP25199613.8A patent/EP4681714A3/en active Pending
- 2020-10-23 JP JP2022523272A patent/JP7766026B2/ja active Active
- 2020-10-23 CA CA3158781A patent/CA3158781A1/en active Pending
- 2020-10-23 EP EP20879266.3A patent/EP4048249B1/en active Active
- 2020-10-23 PT PT208792663T patent/PT4048249T/pt unknown
-
2022
- 2022-04-22 MX MX2025008168A patent/MX2025008168A/es unknown
-
2025
- 2025-10-27 JP JP2025180321A patent/JP2026031955A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| ES3056138T3 (en) | 2026-02-18 |
| WO2021081376A1 (en) | 2021-04-29 |
| KR20220122602A (ko) | 2022-09-02 |
| US20220387396A1 (en) | 2022-12-08 |
| EP4681714A3 (en) | 2026-04-15 |
| EP4048249A1 (en) | 2022-08-31 |
| CN114901270A (zh) | 2022-08-12 |
| IL292367B1 (en) | 2026-04-01 |
| HRP20251489T1 (hr) | 2026-01-02 |
| LT4048249T (lt) | 2026-02-10 |
| JP2026031955A (ja) | 2026-02-25 |
| DK4048249T3 (da) | 2025-12-15 |
| MX2022004910A (es) | 2022-08-18 |
| AU2020370479A1 (en) | 2022-04-28 |
| EP4681714A2 (en) | 2026-01-21 |
| JP7766026B2 (ja) | 2025-11-07 |
| PT4048249T (pt) | 2025-12-02 |
| EP4048249B1 (en) | 2025-09-03 |
| JP2022554090A (ja) | 2022-12-28 |
| EP4048249A4 (en) | 2023-12-13 |
| FI4048249T3 (fi) | 2025-12-05 |
| SI4048249T1 (sl) | 2026-04-30 |
| MX2025008168A (es) | 2025-08-01 |
| IL292367A (en) | 2022-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12377112B2 (en) | Methods of treating neurocognitive disorders, chronic pain and reducing inflammation | |
| AU2017229656B2 (en) | Neuroactive steroids, compositions, and uses thereof | |
| JP2026031955A (ja) | 自閉症スペクトラム障害の症状を治療する方法 | |
| AU2024278543A1 (en) | Improvement in cognitive function with fenfluramine | |
| JP2019529411A (ja) | 不安症およびうつ病の治療のためのプリドピジンの使用 | |
| US20200188358A1 (en) | Methods for the treatment of depression | |
| CN104394866A (zh) | 用于治疗精神和行为病症的药物 | |
| JP6470164B2 (ja) | 精神疾患の治療方法 | |
| WO2016176609A1 (en) | Methods of treating prader-willi syndrome | |
| Volz et al. | Antidepressant drugs and psychomotor performance: A review | |
| RU2844953C1 (ru) | Способы лечения симптомов расстройства аутистического спектра | |
| HK40080588B (en) | Methods of treating the symptoms of autism spectrum disorder | |
| HK40080588A (en) | Methods of treating the symptoms of autism spectrum disorder | |
| IL303006A (en) | Use of pyridofidine and analogues for the treatment of Rett syndrome | |
| AU2016235743A1 (en) | Methods and compositions for the intravenous administration of fumarates for the treatment of neurological diseases | |
| WO2025145241A1 (en) | Treatment of gut-brain interaction disorders | |
| Praschan et al. | 38 Catatonia, Neuroleptic Malignant Syndrome, and Serotonin Syndrome | |
| HK40068315A (en) | Methods of treating neurocognitive disorders, chronic pain and reducing inflammation | |
| CA3257705A1 (en) | TREATMENT OF PATIENTS RESISTANT TO ANTIDEPRESSANTS | |
| Mahoney et al. | 14 Caffeine Effects on Aggression and Risky Decision Making | |
| Makkonen | Childhood autism: aspects of growth factors and monoaminergic transporters in etiopathogenesis | |
| HK40037184A (en) | Use of riluzole prodrugs to treat ataxias | |
| Broekhuizen et al. | AC Baakman1, R. Alvarez-Jimenez1, G. Loewen², ML de Kam1 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220929 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D120 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: VOLUNTARY SUBMISSION OF PRIOR ART RECEIVED Effective date: 20240802 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20240802 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240904 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20240904 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240904 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W200 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST OR RESPONSE SUBMITTED ONLINE Effective date: 20250221 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250224 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D123 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIOR ART DISCLOSURE DETERMINED COMPLIANT Effective date: 20250401 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250401 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250401 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250401 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20250715 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250902 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250902 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20251117 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20260105 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20260105 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260105 |